| Resveratrol inhibits rhabdomyosarcoma cell proliferation. | |
| | |
MedLine Citation:
|
PMID: 16030425 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Rhabdomysarcoma is the most common soft tissue tumour in children under the age of 15. Although the introduction of multimodal treatment programmes, including chemotherapy, radiation therapy and excision have increased the overall survival, the chemotherapeutic agents currently used for the treatment of rhabdomyosarcoma exhibit considerable toxicity. The aim of this study was to investigate the effects and possible mechanism(s) of action of resveratrol on human embryonal rhabdomyosarcoma (RD) cells. Resveratrol is a natural polyphenolic compound produced in a number of edible plants and has received considerable attention as a potential chemopreventive and/or chemotherapeutic agent against various types of cancers. In the present study, resveratrol was shown to inhibit cell proliferation of RD cells in a dose-dependent manner with an IC50 of 48.1 micromol/l and induce an arrest in the S/G2 phase of the cell cycle. As evident from immunocytochemical data, resveratrol treatment increased the size of the RD cells. Furthermore, resveratrol treatment resulted in a significant downregulation of cyclin B expression as demonstrated by western blot analyses. In conclusion, the present study shows that resveratrol exerts a strong inhibition of rhabdomyosarcoma cell proliferation in part by arresting cells in S/G2 phase of the cell cycle. These findings warrant further investigation to establish potential use of resveratrol as a relatively non-toxic chemotherapeutic agent for the treatment of rhabdomyosarcoma. |
| | |
Authors:
|
A W Chow; G Murillo; C Yu; R B van Breemen; A W Boddie; J M Pezzuto; T K Das Gupta; R G Mehta |
Related Documents
:
|
12681445 - Fak overexpression upregulates cyclin d3 and enhances cell proliferation via the pkc an... 19059425 - C-jun/ap-1 pathway-mediated cyclin d1 expression participates in low dose arsenite-indu... 16839745 - Role of pi3k and akt specific isoforms in ovarian cancer cell migration, invasion and p... 9094315 - Phosphorylation and activation of b-myb by cyclin a-cdk2. 7841125 - Responses of rod bipolar cells isolated from dogfish retinal slices to concentration-ju... 10740825 - Circadian control of cell division in unicellular organisms. |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) Volume: 14 ISSN: 0959-8278 ISO Abbreviation: Eur. J. Cancer Prev. Publication Date: 2005 Aug |
Date Detail:
|
Created Date: 2005-07-20 Completed Date: 2005-11-29 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9300837 Medline TA: Eur J Cancer Prev Country: England |
Other Details:
|
Languages: eng Pagination: 351-6 Citation Subset: IM |
Affiliation:
|
Department of Surgical Oncology, College of Medicine, College of Pharmacy, University of Illinois at Chicago, 840 South Wood Street (M/C 820), Chicago, IL 60612, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anticarcinogenic Agents
/
pharmacology* Biopsy, Needle Blotting, Western Cell Cycle / drug effects Cell Proliferation / drug effects* Dose-Response Relationship, Drug Enzyme-Linked Immunosorbent Assay Flow Cytometry Humans Immunohistochemistry Rhabdomyosarcoma / drug therapy, pathology Risk Factors Sensitivity and Specificity Stilbenes / pharmacology* Tumor Cells, Cultured / cytology, drug effects* |
| Chemical | |
Reg. No./Substance:
|
0/Anticarcinogenic Agents; 0/Stilbenes; 501-36-0/resveratrol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Solanum nigrum produces nitric oxide via nuclear factor-kappaB activation in mouse peritoneal macrop...
Next Document: Differences in the characteristics of families with BRCA1 and BRCA2 mutations in Israel.